Penso L, Dray-Spira R, Weill A, et al. - This study was undertaken to investigate the risk of hospitalization or in-hospital mortality due to COVID-19 by treatment exposure in psoriasis patients. Between 2008 and 2019, all adults with psoriasis registered in the French national health insurance database were eligible. Individuals were categorized according to their baseline treatment: biologics, non-biologics, topicals, or no treatment. Researchers distinguished a total of 1,326,312 patients with psoriasis (mean age: 59; men: 48%). It was shown that systemic treatments for psoriasis (including biologics) were not correlated with an elevated risk of in-hospital mortality due to COVID-19. These outcomes illustrate the maintenance of systemic treatment for psoriasis during the pandemic.